Scholar Rock Holding Corporation SRRK
Set alert
As of Nov 3, 10:13 AM ET
- YTD
- -0.20%
- 1 year
- +52.74%
- Open
- 43.37
- Prev close
- 42.91
- Mkt cap
- 5.34B
- Vol
- 57.62K
- Avg vol
- 1.67M
- EPS
- -3.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 43.13
- High
- 44.17
- Forward P/E
- -17.29
- Beta
- 0.79
- Short ratio
- 9.77
- Inst. own
- 118.34%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 10, 2026
- 50-d avg
- 48.47
- 200-d avg
- 48.21
- 1y target
- 70.44
5D chart
Signals (116)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Nov 3, 9:35 AM | 38 minutes ago |
| SMA: Bullish | Nov 3, 9:30 AM | 43 minutes ago |
| SMA: Bullish | Nov 3, 9:30 AM | 43 minutes ago |
| SMA: Bearish | Nov 2, 3:50 PM | 18 hours ago |
| MACD: Sell Signal | Nov 2, 3:50 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 3:45 PM | 18 hours ago |
| MACD: Buy Signal | Nov 2, 3:45 PM | 18 hours ago |
| MACD: Sell Signal | Nov 2, 3:30 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 3:25 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 3:15 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 3:10 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 2:55 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 2:50 PM | 19 hours ago |
| MACD: Buy Signal | Nov 2, 2:50 PM | 19 hours ago |
| MACD: Sell Signal | Nov 2, 2:30 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 2:20 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 2:15 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 2:10 PM | 20 hours ago |
| SMA: Bullish | Nov 2, 2:10 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 2:00 PM | 20 hours ago |
Newest 20 of 116.
News
-
3 weeks ago benzinga.com
Scholar Rock Refiles Marketing Authorisation Application With EMA For Apitegromab To Treat Children And Adults With Spinal Muscular Atrophy
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading…
4 weeks ago benzinga.com
Scholar Rock Holding Reports Q2 2026 Results: Full Earnings Call Transcript
Scholar Rock Holding (NASDAQ:SRRK) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga…
-
1 month ago benzinga.com
Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $77
Truist Securities analyst Srikripa Devarakonda maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $76 to $77.
-
1 month ago benzinga.com
JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $70
JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $63 to $70.
-
1 month ago benzinga.com
Evercore ISI Group Maintains Outperform on Scholar Rock Holding, Raises Price Target to $72
Evercore ISI Group analyst Cory Kasimov maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $65 to $72.
-
1 month ago benzinga.com
Piper Sandler Maintains Overweight on Scholar Rock Holding, Raises Price Target to $75
Piper Sandler analyst Allison Bratzel maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $60 to $75.
-
1 month ago benzinga.com
Jefferies Maintains Buy on Scholar Rock Holding, Raises Price Target to $65
Jefferies analyst Amy Li maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $57 to $65.
1 month ago benzinga.com
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.
-
1 month ago benzinga.com
Wedbush Maintains Outperform on Scholar Rock Holding, Raises Price Target to $70
Wedbush analyst David Nierengarten maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $64 to $70.
1 month ago benzinga.com
Zebra Technologies To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts cut Exodus’ target, raised targets for Teledyne, Roblox, Scholar Rock, Zebra, Agilon, SM Energy and Paymentus; Agilon upgraded to Outperform.
-
1 month ago benzinga.com
Barclays Downgrades Scholar Rock Holding to Equal-Weight, Raises Price Target to $58
Barclays analyst Etzer Darout downgrades Scholar Rock Holding (NASDAQ:SRRK) from Overweight to Equal-Weight and raises the price target from $55 to $58.
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $70
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $65 to $70.
-
1 month ago benzinga.com
Raymond James Maintains Strong Buy on Scholar Rock Holding, Raises Price Target to $72
Raymond James analyst Gary Nachman maintains Scholar Rock Holding (NASDAQ:SRRK) with a Strong Buy and raises the price target from $65 to $72.
-
1 month ago benzinga.com
BMO Capital Maintains Outperform on Scholar Rock Holding, Raises Price Target to $84
BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $76 to $84.
-
1 month ago benzinga.com
Truist Securities Reiterates Buy on Scholar Rock Holding, Raises Price Target to $76
Truist Securities analyst Srikripa Devarakonda reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $55 to $76.
-
1 month ago benzinga.com
Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $74
Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $60 to $74.
1 month ago benzinga.com
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
FDA approves Scholar Rock Isembyld to treat spinal muscular atrophy in adults and pediatric patients two years and older.
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $64 Price Target
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $64 price target.
1 month ago benzinga.com
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $65 price target.
-
2 months ago benzinga.com
Scholar Rock Receives FDA's Fast Track And Orphan Drug Designations For Apitegromab To Treat Facioscapulohumeral Muscular Dystrophy
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading…
-
2 months ago benzinga.com
Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA For The Treatment Of Spinal Muscular Atrophy Under Guidance From The FDA; Now On Track To Submit Apitegromab Japanese New Drug Application By End-2026
FDA review of BLA progressing well with Scholar Rock’s alternate fill-finish facilityCompany is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time…
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $63
JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $56 to $63.
2 months ago benzinga.com
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule
Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping the September 30 approval date on schedule.
-
2 months ago benzinga.com
Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $58 price target.
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $65 price target.
-
2 months ago benzinga.com
Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $60
Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $58 to $60.
-
2 months ago benzinga.com
Scholar Rock Removes Catalent Indiana From Apitegromab BLA After FDA OAI Classification; FDA Review Remains On Track for Sept. 30 PDUFA Using Second Fill-Finish Site
Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish…
-
2 months ago benzinga.com
Scholar Rock Holding Q2 EPS $(0.84) Beats $(0.85) Estimate; Cash Balance Of $492M
Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.85) by 1.18 percent. This is a 14.29 percent increase over losses of…
-
3 months ago benzinga.com
Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $58 price target.
-
3 months ago benzinga.com
Scholar Rock Announces European Medicines Agency Reviewing Apitegromab Marketing Authorisation Application To Treat Spinal Muscular Atrophy; Committee For Medicinal Products For Human Use Anticipated Later This Year If FDA Reclassifies Catalent Indiana
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading…
-
5 months ago benzinga.com
Barclays Maintains Overweight on Scholar Rock Holding, Raises Price Target to $55
Barclays analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $53 to $55.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $65
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $58 to $65.
-
6 months ago benzinga.com
Canaccord Genuity Initiates Coverage On Scholar Rock Holding with Buy Rating, Announces Price Target of $62
Canaccord Genuity analyst Gary Nachman initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) with a Buy rating and announces Price Target of $62.
7 months ago benzinga.com
Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on top names. For a complete view of all rating changes, see analyst ratings page.
-
7 months ago benzinga.com
Wedbush Maintains Outperform on Scholar Rock Holding, Raises Price Target to $58
Wedbush analyst David Nierengarten maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $56 to $58.
7 months ago benzinga.com
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…
-
7 months ago benzinga.com
Scholar Rock Resubmits FDA Biologics License Application For Apitegromab For Spinal Muscular Atrophy, PDUFA Action Date Expected In Late September 2026
Apitegromab BLA resubmission includes Catalent Indiana LLC (part of Novo Nordisk) and second U.S.-based fill-finish facility, aligned with FDA guidance from March 3, 2026 Type C meetingFDA and Novo…
-
7 months ago benzinga.com
JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $50
JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $47 to $50.
-
8 months ago benzinga.com
Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $58
Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $55 to $58.
-
8 months ago benzinga.com
BMO Capital Maintains Outperform on Scholar Rock Holding, Raises Price Target to $70
BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $50 to $70.
-
8 months ago benzinga.com
Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $55
Truist Securities analyst Srikripa Devarakonda maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $44 to $55.
-
8 months ago benzinga.com
Barclays Maintains Overweight on Scholar Rock Holding, Raises Price Target to $53
Barclays analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $52 to $53.
-
8 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $58 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $58 price target.
8 months ago benzinga.com
Scholar Rock Holding: Q4 Earnings Insights
Scholar Rock Holding: Q4 Earnings Insights
11 months ago benzinga.com
Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher
Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher
11 months ago benzinga.com
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday
-
11 months ago benzinga.com
Earnings Scheduled For November 14, 2025
Earnings Scheduled For November 14, 2025
11 months ago benzinga.com
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks
Lucid, Avis, Hims & Hers Health and Upstart are some of the most heavily shorted stocks right now. Here's a look at the top ten.